HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TNDM

Tandem Diabetes Care, Inc. (NASDAQ)

Healthcare — Medical Devices

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Buy 2.0 / 5 20 analysts
$15.99
+$0.24 (+1.52%)
Target: $28.88 (80.6%)
Sign in to add TNDM to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.10B
P/E Ratio (TTM)-
Forward P/E205.58
EPS (TTM)$-1.37
Dividend Yield-
Profit Margin-9.20%
Revenue Growth5.50%
ROE-65.73%
Debt/Equity554.92
Recommendation Buy 2.0
Analyst Target$28.88
Analysts20
Indexes NASDAQ

Technical Indicators

RSI (14)51.3
Beta1.57
SMA 20-
SMA 40-
52-Week High$29.65
52-Week Low$9.98
50-Day Avg$16.83
200-Day Avg$18.64
Avg Volume$2.39M
Volume36.8K

Performance Analysis

NEUTRAL

TNDM presents a mixed picture with both positive and negative indicators.

~ Trading at 31% of its 52-week range.
~ RSI at 51.3 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 5.5% year-over-year.
- Operating at a loss with -9.2% margin.
+ Wall Street consensus is "Buy" from 20 analysts.
+ Average analyst target of $28.88 implies 80.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:34 UTC

Back to Screener Export Report